Actinium Pharmaceuticals Inc - ESG Rating & Company Profile powered by AI
The ESG score covers 17 UN SDGs including: 'Gender Equality', 'Responsible Production & Consumption' and 'Peace, Justice & Strong Institutions'. If you are employed by Actinium Pharmaceuticals Inc and you would like to use your Sustainability aseessment, please get in touch. This page displays a zero-cost Sustainability assessment for Actinium Pharmaceuticals Inc.
Actinium Pharmaceuticals Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.0; made up of an environmental score of 5.3, social score of 4.8 and governance score of 8.0.
6.0
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
483 | Wakamoto Pharmaceutical Co Ltd | 6.1 | High |
483 | aTyr Pharma Inc | 6.1 | High |
498 | Actinium Pharmaceuticals Inc | 6.0 | High |
498 | Cann Group Ltd | 6.0 | High |
498 | Biosynex SA | 6.0 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Actinium Pharmaceuticals Inc have an accelerator or VC vehicle to help deliver innovation?
Does Actinium Pharmaceuticals Inc disclose current and historical energy intensity?
Does Actinium Pharmaceuticals Inc report the average age of the workforce?
Does Actinium Pharmaceuticals Inc reference operational or capital allocation in relation to climate change?
Does Actinium Pharmaceuticals Inc disclose its ethnicity pay gap?
Does Actinium Pharmaceuticals Inc disclose cybersecurity risks?
Does Actinium Pharmaceuticals Inc offer flexible work?
Does Actinium Pharmaceuticals Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Actinium Pharmaceuticals Inc disclose the number of employees in R&D functions?
Does Actinium Pharmaceuticals Inc conduct supply chain audits?
Does Actinium Pharmaceuticals Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Actinium Pharmaceuticals Inc conduct 360 degree staff reviews?
Does Actinium Pharmaceuticals Inc disclose the individual responsible for D&I?
Does Actinium Pharmaceuticals Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Actinium Pharmaceuticals Inc disclose current and / or historical scope 2 emissions?
Does Actinium Pharmaceuticals Inc disclose water use targets?
Does Actinium Pharmaceuticals Inc have careers partnerships with academic institutions?
Did Actinium Pharmaceuticals Inc have a product recall in the last two years?
Does Actinium Pharmaceuticals Inc disclose incidents of discrimination?
Does Actinium Pharmaceuticals Inc allow for Work Councils/Collective Agreements to be formed?
Has Actinium Pharmaceuticals Inc issued a profit warning in the past 24 months?
Does Actinium Pharmaceuticals Inc disclose parental leave metrics?
Does Actinium Pharmaceuticals Inc disclose climate scenario or pathway analysis?
Does Actinium Pharmaceuticals Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Actinium Pharmaceuticals Inc disclose the pay ratio of women to men?
Does Actinium Pharmaceuticals Inc support suppliers with sustainability related research and development?
Does Actinium Pharmaceuticals Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Actinium Pharmaceuticals Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Actinium Pharmaceuticals Inc involved in embryonic stem cell research?
Does Actinium Pharmaceuticals Inc disclose GHG and Air Emissions intensity?
Does Actinium Pharmaceuticals Inc disclose its waste policy?
Does Actinium Pharmaceuticals Inc report according to TCFD requirements?
Does Actinium Pharmaceuticals Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Actinium Pharmaceuticals Inc disclose energy use targets?
Does Actinium Pharmaceuticals Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Actinium Pharmaceuticals Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Actinium Pharmaceuticals Inc
These potential risks are based on the size, segment and geographies of the company.
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.